Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, is pleased to announce that Junson Capital has joined its investor syndicate. Junson Capital has joined the existing investors including KCK MedTech, Panakes, Supernova Invest, and Exor Ventures to complete the Series B financing.

Allotex Inc. is a pioneering biologics and device company focused on developing innovative therapeutic solutions for vision correction. By utilizing precisely shaped human corneal allografts, Allotex creates a natural, removable inlay, offering patients a safe, permanent vision correction option. With a commitment to advancing vision correction, Allotex is dedicated to improving the lives of individuals affected by presbyopia and other refractive disorders of the human eye.